(TLRY) Tilray - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 633m USD | Total Return: 19.8% in 12m
Avg Turnover: 18.5M
Qual. Beats: 0
Rev. Trend: 92.4%
Qual. Beats: 0
Warnings
Share dilution 24.0% YoY
Interest Coverage Ratio -67.6 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Tilray Brands, Inc. is a diversified consumer products firm headquartered in Canada, specializing in medical and adult-use cannabis, alcoholic beverages, and wellness products. The company operates across four primary segments: Cannabis, Beverage, Distribution, and Wellness, maintaining a presence in North America, Europe, and several international markets. Its portfolio includes a wide range of brands such as Aphria, SweetWater Brewing, and Manitoba Harvest, targeting diverse consumer bases from healthcare providers to retail beverage shoppers.
The company has aggressively transitioned into the craft beer and spirits sector to diversify revenue streams beyond the volatile cannabis market. This vertical integration strategy allows Tilray to leverage its existing distribution networks for both hemp-based wellness products and traditional consumer packaged goods. Investors should note that the cannabis sector remains highly sensitive to shifting federal regulations in the United States and Germany.
For more detailed insights into the companys financial health, consult ValueRay. It is important to monitor how the company balances its high-cost pharmaceutical distribution with the growth of its beverage alcohol division.
- Strategic expansion into craft beer market diversifies revenue and improves cash flow
- Potential US federal cannabis reclassification significantly impacts valuation and market access
- Market share leadership in Canadian adult-use cannabis drives core revenue growth
- High debt levels and share dilution risks influence long-term investor sentiment
- European medical cannabis expansion relies on evolving regional legalization and regulatory shifts
| Net Income: -1.85b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -2.25 > 1.0 |
| NWC/Revenue: 39.02% < 20% (prev 53.43%; Δ -14.41% < -1%) |
| CFO/TA -0.03 > 3% & CFO -55.8m > Net Income -1.85b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.7m) vs 12m ago 24.05% < -2% |
| Gross Margin: 27.67% > 18% (prev 0.31%; Δ 2.74k% > 0.5%) |
| Asset Turnover: 33.82% > 50% (prev 23.32%; Δ 10.49% > 0%) |
| Interest Coverage Ratio: -67.61 > 6 (EBITDA TTM -1.84b / Interest Expense TTM 28.9m) |
| A: 0.22 (Total Current Assets 718.8m - Total Current Liabilities 257.5m) / Total Assets 2.07b |
| B: -2.37 (Retained Earnings -4.92b / Total Assets 2.07b) |
| C: -0.56 (EBIT TTM -1.96b / Avg Total Assets 3.50b) |
| D: -9.04 (Book Value of Equity -4.96b / Total Liabilities 549.1m) |
| Altman-Z'' = -19.52 = D |
| DSRI: 0.77 (Receivables 118.4m/149.3m, Revenue 1.18b/1.15b) |
| GMI: 1.11 (GM 27.67% / 30.83%) |
| AQI: 1.02 (AQ_t 0.64 / AQ_t-1 0.64) |
| SGI: 1.03 (Revenue 1.18b / 1.15b) |
| TATA: -0.86 (NI -1.85b - CFO -55.8m) / TA 2.07b) |
| Beneish M = -3.97 (Cap -4..+1) = AAA |
As of May 30, 2026, the stock is trading at USD 5.51 with a total of 3,303,582 shares traded.
Over the past week, the price has changed by +0.92%,
over one month by -10.26%,
over three months by -29.99% and
over the past year by +19.78%.
Tilray has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold TLRY.
- StrongBuy: 4
- Buy: 0
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10 | 82.2% |
P/E Forward = 1000.0
P/S = 0.7372
P/B = 0.4063
Revenue TTM = 1.18b USD
EBIT TTM = -1.96b USD
EBITDA TTM = -1.84b USD
Long Term Debt = 223.2m USD (from longTermDebt, last quarter)
Short Term Debt = 33.5m USD (from shortTermDebt, last quarter)
Debt = 384.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 67.5m
Net Debt = 164.7m USD (calculated: Debt 384.6m - CCE 219.9m)
Enterprise Value = 797.4m USD (632.7m + Debt 384.6m - CCE 219.9m)
Interest Coverage Ratio = -67.61 (Ebit TTM -1.96b / Interest Expense TTM 28.9m)
EV/FCF = -8.33x (Enterprise Value 797.4m / FCF TTM -95.7m)
FCF Yield = -12.00% (FCF TTM -95.7m / Enterprise Value 797.4m)
FCF Margin = -8.10% (FCF TTM -95.7m / Revenue TTM 1.18b)
Net Margin = -156.2% (Net Income TTM -1.85b / Revenue TTM 1.18b)
Gross Margin = 27.67% ((Revenue TTM 1.18b - Cost of Revenue TTM 854.9m) / Revenue TTM)
Gross Margin QoQ = 26.58% (prev 26.43%)
Tobins Q-Ratio = 0.38 (Enterprise Value 797.4m / Total Assets 2.07b)
Interest Expense / Debt = 7.52% (Interest Expense 28.9m / Debt 384.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.54b (EBIT -1.96b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.79 (Total Current Assets 718.8m / Total Current Liabilities 257.5m)
Debt / Equity = 0.25 (Debt 384.6m / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = -0.09 (negative EBITDA) (Net Debt 164.7m / EBITDA -1.84b)
Debt / FCF = -1.72 (negative FCF - burning cash) (Net Debt 164.7m / FCF TTM -95.7m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = -52.82% (Net Income -1.85b / Total Assets 2.07b)
RoE = -26.72% (Net Income TTM -1.85b / Total Stockholder Equity 6.91b)
RoCE = -27.42% (EBIT -1.96b / Capital Employed (Equity 6.91b + L.T.Debt 223.2m))
RoIC = -94.73% (negative operating profit) (NOPAT -1.54b / Invested Capital 1.63b)
WACC = 10.89% (E(632.7m)/V(1.02b) * Re(13.90%) + D(384.6m)/V(1.02b) * Rd(7.52%) * (1-Tc(0.21)))
Discount Rate = 13.90% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 21.22%
[DCF] Fair Price = unknown (Cash Flow -95.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.17 | # QB: 0
Revenue Correlation: 92.39 | Revenue CAGR: 12.70% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-08-31): EPS=-0.13 | Chg30d=N/A | Revisions=-20% | Analysts=4
EPS current Year (2026-05-31): EPS=-0.08 | Chg30d=N/A | Revisions=-20% | GrowthEPS=-179.1% | GrowthRev=+7.7%
[Analyst] Revisions Ratio: -20%